ArticleResearch square2026
Disparities in Timeliness of Cancer Diagnosis Across a Multi-Site Academic Health System.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Background: Early cancer diagnosis improves survival and quality of life, yet disparities in stage at diagnosis persist. This study evaluates demographic, clinical, insurance, and neighborhood-level socioeconomic factors associated with late-stage cancer diagnosis within an academic health system. Methods: We conducted a retrospective cohort study of 27,064 adults diagnosed with breast, colorectal, or lung and bronchus cancer between 2015 and 2025 in the University of California Health System. Late-stage disease was defined as AJCC stage III/IV. Multivariable logistic regression examined associations between late-stage diagnosis and patient characteristics, insurance status, comorbidity burden, and neighborhood socioeconomic measures, including the Area Deprivation Index (ADI), Social Vulnerability Index (SVI), and Healthy Places Index (HPI). Results: 17.6% of patients were diagnosed at a late stage. Cancer type was the strongest predictor, with lung (aOR ≈ 13-14) and colorectal cancer (aOR ≈ 8) associated with higher odds of late-stage diagnosis compared with breast cancer. Residence in medium and high ADI tertiles and Medicaid insurance (OR = 1.16; 95% CI: 1.06-1.28) were associated with higher odds of late-stage diagnosis, while Veterans Affairs coverage was associated with lower odds (OR = 0.76; 95% CI: 0.58-1.01). SVI was not associated with stage at diagnosis, whereas higher HPI scores were modestly protective. Conclusion: Late-stage cancer diagnosis is driven primarily by cancer type and insurance status, with additional contributions from neighborhood disadvantage.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.